Competitor Analysis: RSV Vaccines and Therapeutics

Date: June 2, 2012
Pages: 30
US$ 315.00
License [?]:
Publisher: La Merie Publishing
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: C489D890AF9EN

Download PDF Leaflet

Competitor Analysis: RSV Vaccines and Therapeutics
Competitor Analysis: Respiratory Syncytial Virus (RSV) Vaccines and Therapeutics

The present Competitive Intelligence Report about RSV Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules and RNAi against infection with respiratory syncytial virus (RSV) as of June 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

Respiratory syncytial virus (RSV) infection, which manifests primarily as bronchiolitis and/or viral pneumonia, is the leading cause of lower respiratory tract infection in infants and young children. In the US, RSV LRT infection develops annually in 4-5 million children, and more than 125,000 children are admitted per year for RSV-related illness. RSV disease is the no.1 cause of hospitalization in babies under a year of age in the US. While a monoclonal antibody is commercially available to help prevent RSV disease in infants and children at high risk for severe lung disease from RSV, a RSV vaccine still is not on the market. A number of RSV vaccine candidates have entered clinical development and further are to follow. Also, next generation antibodies against RSV with improved features are in the development pipeline as well as new therapies based on silencing RSV RNA or inhibiting key targets of the virus.

The report includes a compilation of currently active projects in development of vaccines, antibodies, small molecules and small interfering RNA (siRNA) targeting respiratory syncytial virus for prophylaxis and treatment of RSV infections. In addition, the report lists company-specific R&D pipelines of RSV Vaccines & Therapeutics. Competitor projects are listed in a tabular format providing information on:
  • Drug Codes,
  • Target / Mechanism of Action,
  • Class of Compound,
  • Company,
  • Product Category,
  • Indication,
  • R&D Stage and
  • additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
  • RSV Vaccines
  • Antibody-Based RSV Therapeutics
  • Other Biologics as RSV Therapeutics
  • Small Molecule RSV Therapeutics
  • Corporate RSV Vaccines & Therapeutics R&D Pipeline
  • About La Merie

Skip to top

Competitor Analysis: Anthrax Vaccines & Therapeutics US$ 257.00 Jun, 2013 · 32 pages
Competitor Analysis Influenza Vaccines US$ 718.00 May, 2011 · 123 pages
Competitor Analysis: Cancer Vaccines US$ 1,112.00 Mar, 2014 · 179 pages
Competitor Analysis HIV Vaccines US$ 413.00 Oct, 2011 · 54 pages
Competitor Analysis: Malaria Vaccines & Therapeutics US$ 390.00 Aug, 2012 · 64 pages

Ask Your Question

Competitor Analysis: RSV Vaccines and Therapeutics
Company name*:
Contact person*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: